pemigatinib
oral FGFR1/2/3 kinase inhibitor approved in oncology, 13.5 mg QD (14d+, 7d-) from focused screen of ~20k cmpds and SBDD Journal of Medicinal Chemistry Incyte Corporation, Wilmington, US
Molecules of the Month - July 2021
Molecules of the Month
- giredestrant
- pemigatinib
- ceralasertib (AZD6738)
- VIP152 (BAY 1251152)
- TAK-653
- TAK-071
- TAK-041
- TAK-906
- KZR-616
- "compound 10"
- PTC596
- "compound 10"
- GSK852
- compound 59